Published in Gene Therapy Weekly, March 17th, 1997
This is the second Phase I clinical trial that ONYX has initiated with ONYX-015. The first Phase I study, directed at head and neck tumors, began in April 1996.
ONYX-015 is a genetically engineered adenovirus that efficiently replicates in and kills tumor cells deficient in the p53 tumor suppressor gene product. Mutations in p53 are the most common type of genetic abnormality in cancer, occurring in more than 50 percent of human cancer cases, including more than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.